

WALSH ABSTRACT GUIDELINE - NANOS 52nd Annual Meeting

March 20th – 24th, 2026 Marriott Copley Place, Boston, MA

Abstract Submission Deadline: 11:59 PM EDT on OCTOBER 23rd, 2025 (Thursday)

The Frank B. Walsh Session opens the NANOS Annual Meeting on March 21st, 2026 (Saturday). All accepted abstracts will be presented orally as part of the Frank B. Walsh Session.

The Walsh Session will consist of short presentations and discussions of interesting, unusual and instructive cases in which the diagnosis is supported by pathologic material, bacteriologic cultures, laboratory analyses, etc. Pathologic material is encouraged but not required for acceptance. We also encourage submission of pediatric cases and cases with interesting genetic testing. Titles should not reveal the final diagnosis and should be relevant to the case material.

The 2026Host Committee that will select the cases includes Harvard Medical School, Boston, MA

Host in Charge: Gena Heidary, MD, PhD

Host Committee Members:

Joseph Rizzo III, MD

Eric Gaier, MD, PhD

Ryan Gise, MD

Tais Estrela, MD

Expert Panel:

Neuroradiologist: Mary Beth Cunnane, MD (adult) Caroline D. Robson, MBChB, FASPNR (pediatric) Neuropathologist: Matthew Frosch, MD, PhD

Ophthalmic Pathologist and Dermatopathologist: Anna M. Stagner, MD

IMORTANT

- Walsh submissions not accepted for presentation may be given the opportunity to resubmit as a Descriptive Studies poster if they are above the mean score of the Walsh committee rating.
- Only one submission per first/presenting author is allowed per abstract category.

Abstract Submission Instructions

The deadline for submission of abstracts is October 23rd, 2025. Submissions received after this date will not be accepted.

To submit an abstract, click HERE. You will be asked to complete an abstract form and electronically submit

representative radiology and pathology images (images must be uploaded as one PowerPoint).

Please upload representative radiology and/or pathology slide images in PowerPoint format. All photos *must be high resolution*, or they will not display well on a larger projection if your case is accepted for presentation. For all images (radiology or pathology), there should be clear identification of their timing relative to the case both in the image PowerPoint and as callouts in the case text. Imaging sequences and pathology magnification and stains should be noted on the images. No word document, PDF or single images in JPEG, TIFF, or Photoshop will be accepted. Please make sure the author's name is NOT listed in the slides (as the reviews/selection process is blinded).

Pathology glass slides and complete imaging may be requested if selected for presentation, but do not have to be submitted initially.

You will be notified of acceptance of your abstract in November 2025.

If accepted for a Walsh presentation, you will be required to submit your final presentation in PowerPoint or Keynote format approximately 3 weeks prior to the meeting. Failure to do so may result in removal from the scheduled program. Your final presentation will be reviewed by the Host Committee for CME compliance, material that may be offensive on the basis of gender, body image, group characteristics, or grammatical errors, HIPAA compliance, and length. You may be asked to make changes to the final presentation as a result of the review process. Our third-party CME accreditor may also request to review your presentation to ensure CME compliance.

The auditorium is set up for PowerPoint presentations using computer projection in 16:9 format and will have video capability.

Walsh speakers should abide by the <u>NANOS speaker policy</u>.

All platform/Walsh acceptances are subject to CME approval and no employees of *ineligible companies** can present.

Submitting an Abstract

Important Information

- Presenting authors must have completed an MD or equivalent except in rare exceptions and preapproval from the Walsh committee. All presenters will be required to meet the evening prior to the session to participate in an on-site rehearsal.
- If you are a fellow-in-training or resident submitting an abstract, you must submit the name of the senior author during the submission process, in addition to listing their full details in the Co-Authors section of the submission form.
 - Fellows-in-training/Residents: The senior author must be a NANOS member who is familiar with the Walsh Meeting, will mentor you with the presentation and will be present at the NANOS meeting. All fellows-in-training/residents must review prior Walsh Session videos (link 1 and link2) on the NANOS website prior to presentation. The senior author/mentor will be copied on all communication between the Host committee and the presenter. Your mentor must review all draft presentations before submitting them for review to the Host Committee.
- Avoid trade names whenever possible. Sometimes you need to say the trade name at least once, for clarity. For instance, natalizumab (Tysabri).
- NANOS will not accept abstracts that have been accepted for publication at the time of submission.

Preparation of Your Abstract

- No identifying features such as names of hospitals, medical schools, clinics, or cities may be
 listed in the title or text of the abstract. Do not include the names of authors either. The names
 of authors and their affiliations (institutions) will be submitted online when you submit the
 abstract.
- Titles are at the author's discretion. Please keep them relevant to the case material; the review committee may request a title change.
- All authors that had influence over the content of the abstract must disclose relevant financial relationships. When submitting the abstract online, please list the names of the authors and the corresponding financial disclosures.
- Six items are needed for submission of your Walsh case:
 - 1. History & Exam abstract (<300 words)
 - 2. Case Summary with References (<300 words)
 - 3. Case Dilemmas e.g., difficult decision making, incorrect diagnoses (<75 words)
 - 4. Final diagnosis (ideally one sentence or <75 words)
 - 5. Describe why your presentation is unique (<75 words)
 - 6. Two/Three teaching points
 - 7. Representative Radiology Images (<10), additional images may be required for review
 - 8. Representative Pathology Images (<10), additional images may be required for review
- Please be sure to label any images you upload (part of case, imaging sequence, pathology stain, magnification, etc.).
- Crop out any patient identifiers in any images you upload.

Withdrawing an Abstract

If you want to withdraw a submitted abstract, please contact the NANOS Meetings & Marketing Manager at meetings@nanosweb.org.

- * *Ineligible companies*: companies that are ineligible to be accredited in the ACCME System (now known as **ineligible companies**) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Examples of such organizations include:
 - o Advertising, marketing, or communication firms whose clients are ineligible companies
 - o Bio-medical startups that have begun a governmental regulatory approval process
 - Compounding pharmacies that manufacture propriety compounds
 - Device manufacturers or distributors
 - Diagnostic labs that sell propriety products
 - o Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
 - Manufacturers of health-related wearable products
 - Pharmaceutical companies or distributors
 - Pharmacy benefit managers

o Reagent manufacturers or sellers